MSB

2.03%

$1.45 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-108

First 108 Last

Share
Profile

Follow
anf0

1,971 Posts.

187

02/10/20

19:23

Post #: 47821470
Share

Originally posted by Zenox: ↑

It is definitely probable Mesoblast and the FDA entered into some type of correspondence following the ODAC meeting, but these would not have been formal or detailed discussions.

It appears the FDA went with their original stance and ignored the recommendation of the ODAC committee, expert testimony, and the clinical benefit to children. It seems the FDA simultaneously applied a low threshold for rejection and a high threshold for approval. Maybe the current political climate played a role since there has been some serious scrutiny surrounding the FDA in the last few months, and September has been a particularly bad month for approvals. Maybe the petition from Lassman Law play a part as well. Overall it seems the FDA believes Ryoncil just missed the regulatory requirements for approval.

The best way I can explain the FDA approval process is to use an example where a patient goes into a hospital to see a doctor. Normally they will see a lower ranked doctor first (let's say a trainee or a registrar), who are the first to evaluate the patient. The registrar will consult other specialists to obtain an accurate assessment of the patient (or in this case Mesoblast's BLA application) and they will make a diagnosis (approval or not). Sometimes the diagnosis will be in dispute and the case will be escalated to the consultant (highest ranking doctor) who will make a more informed assessment of the patients condition.

Mesoblast have a clear case to take to the FDA to dispute this decision and there are precedents that work in their favour. As I understand it, Mesoblast will need to submit an application containing key information supporting approval (this cannot include new information) and this will be viewed by those higher up in the chain of command who will have to apply precedents to their decision making. The key difference here is they need to apply precedents. Today's CRL leads me to believe that the FDA does not want to set a new precedent by approving Ryoncil, but following a Type A meeting they can apply other precedents to facilitate approval. As SI said today, this is just part of a process.

Should we be concerned? No not yet. Maybe if they deny the Type A meeting, then sure. But even then, we still have COVID ARDs, CLBP and Heart readouts to come - all blockbusters.

Expand

I encourage you to read this if you’re truly interested in the facts. It’s by far the best analysis on this treatment I’ve seen, and just to warn you it tilts against FDA approval.

https://mobile.twitter.com/BiotechSacred/status/1293897790557425664

And FYI I shared it during the ODAC meeting and got obliterated from every direction. I was just trying to share some important information.

Last edited by anf0: 02/10/20

MSB Price at posting: $3.19 Sentiment: Sell Disclosure: Not Held
6 Upvote

0 Great analysis

Reply

Top Stories

SGR

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

TLX

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

TYP

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

THB

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

YAL

Yancoal Australia reports strong Q3 financials

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

M4M

Macro and Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

There are more pages in this discussion • 910 more messages in this thread...

First 108 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.45		Change -0.030(2.03%)		Mkt cap ! $1.655B

Open	High	Low	Value	Volume
$1.48	$1.51	$1.43	$6.613M	4.498M

Buyers (Bids)

No.	Vol.	Price($)
1	2482	$1.45

Sellers (Offers)

Price($)	Vol.	No.
$1.46	27045	2

View Market Depth

No.	Vol.	Price($)
1	2482	1.450
2	5794	1.445
6	50901	1.440
4	52442	1.435
5	177906	1.430

Price($)	Vol.	No.
1.455	27045	2
1.460	64331	5
1.465	35901	2
1.470	54504	2
1.480	132521	3

Last trade - 16.10pm 18/10/2024 (20 minute delay)

MSB (ASX) Chart

MSB to dispute FDA finding in Type A meeting, page-108

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

Yancoal Australia reports strong Q3 financials

Talga Group wins key permit for flagship graphite mine in Sweden

Macro and Norden set up transport solutions initiative for West Pilbara

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB to dispute FDA finding in Type A meeting, page-108

Top Stories

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

Yancoal Australia reports strong Q3 financials

Talga Group wins key permit for flagship graphite mine in Sweden

Macro and Norden set up transport solutions initiative for West Pilbara

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News